Eli Lilly and Company (LLY)
Eli Lilly and Company (LLY) Q4 2024 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY ) Q4 2024 Results Conference Call February 6, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of Investor Relations David Ricks - Chair and CEO Lucas Montarce - Chief Financial Officer Dr. Dan Skovronsky - Chief Scientific Officer & President of Lilly Immunology Patrik Jonsson - President of Lilly Cardiometabolic Health & Lilly USA Dave Hyman - Chief Medical Officer Anne White - President of Lilly Neuroscience Jake Van Naarden - President of Lilly Oncology Ilya Yuffa - President of Lilly International Marc Kemen - Investor Relations Wes Taul - Investor Relations Wai Wong - Investor Relations Conference Call Participants Tim Anderson - Bank of America Terence Flynn - Morgan Stanley Courtney Breen - Bernstein Chris Schott - JPMorgan Geoff Meacham - Citibank Colleen Garvey - Guggenheim Securities Conor MacKay - BMO Capital Markets Umer Raffat - Evercore Steve Scala - TD Cowen Mohit Bansal - Wells Fargo Dave Risinger - Leerink Partners Akash Tewari - Jefferies Alexandria Hammond - Wolfe Research Chris Shibutani - Goldman Sachs James Shin - Deutsche Bank Trung Huynh - UBS Nicole Germino - Truist Securities Operator Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q4 2024 Earnings Call. At this time all participants are in a listen-only mode.
Compared to Estimates, Lilly (LLY) Q4 Earnings: A Look at Key Metrics
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates
Eli Lilly beats fourth-quarter estimates for earnings and sales. Mounjaro and Zepbound sales miss estimates.
Why Eli Lilly Stock Popped on Thursday
Eli Lilly (LLY 4.07%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report.
LLY Gains on Weight Loss Drugs, F Tariff Fears, HON Split
Eli Lilly (LLY) shares ran higher following its earnings report with its weight loss drugs in focus. Ford Motor Co. (F) hit a 52-week low with tariffs from President Trump posing questions around the company's outlook.
Eli Lilly Q4 earnings beat as weight loss drug sales miss estimates
Eli Lilly and Co (NYSE:LLY) reported mixed results for the fourth quarter, with earnings outpacing estimates as revenue from its weight loss drugs Mounjaro and Zepbound fell short. Revenue surged 45% year-over-year to $13.53 billion, slightly below the $15.37 billion expected by Wall Street analysts.
Eli Lilly (LLY) Q4 Earnings and Revenues Top Estimates
Eli Lilly (LLY) came out with quarterly earnings of $5.32 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $2.49 per share a year ago.
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
On Thursday, Eli Lilly and Co LLY stock is trading higher after the company released better-than-expected fourth-quarter earnings and provided 2025 guidance.
Lilly says Mounjaro and Zepbound contributed to big revenue boost
Lilly's CEO says that the company has “tremendous momentum” entering 2025.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a few months earlier than expected. The company expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short
Eli Lilly (LLY) reported mostly worse-than-expected fourth-quarter results Thursday, but the drugmaker's adjusted profit came in above estimates.
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
CNBC's Angelica Peebles joins 'Squawk Box' to report on the company's quarterly earnings results.
